A gene therapy company long defined by its losses and its promises has crossed a threshold that few in its position manage to reach: it turned a profit, and a substantial one. MeiraGTx reported a dramatic reversal in the second quarter of 2026, moving from tens of millions in losses to over $160 million in net income on revenue that multiplied nearly ninety-fold year over year. The arrival of seasoned commercialization executives alongside these numbers signals that the company believes it has moved from the age of survival into the age of execution — a transition that is, in biotech, rarer an